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Background: Anxiety is common in patients with cognitive impairment and dementia.
However, whether anxiety is a risk factor for dementia is still not known. We aimed to
examine the association between trait anxiety at baseline and the 10-year risk of incident
dementia to determine to which extent depressive symptoms influence this relationship
in the general population.
Methods: Data came from 5,234 community-dwelling participants from the Three-City
prospective cohort study, aged 65 years at baseline and followed over 10 years. At
baseline, anxiety trait was assessed using the Spielberger State-Trait Anxiety Inventory
(STAI), and depressive symptoms using Center for Epidemiologic Studies-Depression
Scale (CESD). Use of anxiolytic drugs was also considered. Diagnoses of dementia
were made at baseline and every 2 years. To examine the relationship between anxiety
exposures and risk of incident dementia, Cox proportional hazard regression models
were performed.
Results: Taking anxiolytic drugs or having high trait anxiety (STAI score ≥ 44) increased
the risk of dementia assessed over 10 years of follow-up [Hazard Ratio (HR) = 1.39,
95%CI: 1.08–1.80, p= 0.01 and HR= 1.26, 95%CI: 1.01–1.57, p= 0.04, respectively],
independently of a large panel of socio-demographic variables, health behaviors,
cardio-metabolic disorders, and additional age-related disorders such as cardiovascular
diseases, activity limitations, and cognitive deficit. However, the associations were
substantially attenuated after further adjustment for depressive symptoms.
Conclusion: Our findings suggest that depressive symptoms shape the association
between anxiety trait and dementia. Further research is needed to replicate our findings
and extrapolate our results to anxiety disorders.
Keywords: anxiety, Spielberger State-Trait Anxiety Inventory, depressive symptoms, aging, dementia, risk factors,
prospective cohort
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INTRODUCTION
Anxiety and depression are common in patients with cognitive
impairment and dementia (Lyketsos et al., 2002; Geda et al.,
2008; Steinberg et al., 2008; Ausén et al., 2009; Rosenberg et al.,
2011). The high prevalence of those neuropsychiatric symptoms
reported in cognitive impaired populations raises the question
of the exact nature of their relationships and the causality
link regarding age-related cognitive disorders (Livingston et al.,
2017).
Depression has been extensively studied in relation to
dementia and Alzheimer’s disease. Even if its role-prodrome
(Heser et al., 2013; Singh-Manoux et al., 2017) or risk factor
(Jorm, 2000)-is still under debate, its independent association
with dementia has been evidenced. In contrast, very few
studies examined whether anxiety is independently associated
with cognitive aging outcomes. Anxiety is often viewed as
a psychological reaction to cognitive deterioration and most
studies examining the anxiety-cerebral aging outcomes are
cross-sectional, making an assessment of the direction of the
association impossible. Amongst the few available prospective
studies (Palmer et al., 2007; Devier et al., 2009; Gallacher
et al., 2009; Wilson et al., 2011; Rosenberg et al., 2013), a
positive association between anxiety and dementia has been
reported in two studies (Wilson et al., 2011; Kassem et al.,
2017), but not in Gallacher et al.’s study, carried out in general
populations (Gallacher et al., 2009). Similar inconsistencies have
been reported in the literature examining associations between
anxiety and risk of transition to dementia in Mild Cognitive
Impairment (MCI—a prodromal state of dementia) patients
(Palmer et al., 2007; Teng et al., 2007; Devier et al., 2009;
Ramakers et al., 2010; Rosenberg et al., 2013).
The differences in anxiety assessment, the follow-up
duration generally lower than 5 years (precluding to
account the preclinical phase of dementia during which
dementia physiopathological processes are active), the sample
heterogeneity, and the choice of adjustment variables may partly
explain those inconsistent findings. In particular, depression,
a frequent comorbidity of anxiety (Beekman et al., 2000;
Zimmerman et al., 2000) which could share some risk factors
(Roy et al., 1995; Grant et al., 2009) or even could be initiated by
anxiety (Potvin et al., 2013), is not considered systematically as
an adjustment factor in every study while it appears to attenuate
the relationship between anxiety and risk of dementia (Gallacher
et al., 2009).
The main objective of the present study was to examine
the association between the risk of incident dementia and
trait anxiety -a measure of individual differences in anxiety-
proneness which reflects the tendency to perceive stressful
situations as dangerous or threatening (Spielberger, 1983)-
in an elderly general population over a 10-year follow-up
period. Remaining relatively stable over time and being more
related to personality than state anxiety, trait anxiety is likely
to be present before the clinical manifestations of dementia
and we hypothesized that it could be associated with an
increased dementia risk. Additionally, because of their frequent
overlap, we aimed to determine the influence of depressive




Participants were recruited as part of a multisite cohort study
of community-dwelling older adults conducted in three French
cities Bordeaux, Dijon, and Montpellier between 1999 and
2001: The Three-City (3C) Study (3C Study Group, 2003).
The inclusion criteria were to be living in these cities or their
suburbs and registered on the electoral rolls, to be aged 65
years and over, and not to be institutionalized. The cohort
size was set at 10,000 participants (2,500 in Bordeaux, 2,500
in Montpellier, and 5,000 in Dijon) and administrative districts
were selected in each city accordingly. Eligible inhabitants of the
selected districts were invited to participate through a personal
letter.
Of the 9,294 participants originally included (acceptance
rate of 37%), we excluded 214 with dementia diagnosed at
baseline clinical examination (1999–2001). We further excluded
487 participants with cognitive impairment assessed by a Mini
Mental State Examination (MMSE) score ≤ 24 at baseline
(Figure 1).
Seven hundred and forty-six participants did not have the
next follow-ups (at 2, 4, 8, and 10 years after baseline). The
present analyses carried out on 5,234 participants for whom
complete and validated data on anxiety, depressive symptoms,
dementia diagnosis, and covariates were available as detailed
in the flow-chart diagram (Figure 1). Compared to participants
included, the 3,357 excluded participants were significantly older
and were more likely to have high score in anxiety and depressive
symptoms scales and lower cognitive performances at baseline
(data available on request).
Standard Protocol Approvals, Registrations, and
Patient Consents
The study protocol was approved by the Ethics Committee of the
Hospital of Kremlin-Bicêtre and Sud-Méditerranée III. A written
informed consent was obtained from all patients participating in
the study (consent for research).
Incidence of Dementia Over 10 Years
At baseline, diagnosis of dementia was based on a 3-
step procedure (3C Study Group, 2003; Akbaraly et al.,
2009). First, trained psychologists administered a battery
of neuropsychological tests detailed elsewhere (3C Study
Group, 2003). Second, all the participants in Montpellier
were then examined by a neurologist, whereas in Dijon and
Bordeaux, because of the larger number of participants, only
those who screened positive underwent further examination.
Finally, an independent committee of neurologists reviewed
all potential prevalent and incident cases of dementia to
obtain a consensus on its diagnosis and etiology according
to the criteria of the Diagnostic and Statistical Manual
of Mental Disorders, fourth edition (American Psychiatry
Association, 2000). Cases of Alzheimer’s Disease (AD) were
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FIGURE 1 | Sample analysis.
classified according to the National Institute of Neurological and
Communicative Disorders and Stroke–Alzheimer’s Disease and
Related Disorders Association (McKhann et al., 1984) and cases
of mixed/vascular dementia according to the National Institute
of Neurological Disorders and Stroke–Association Internationale
pour la Recherche en l’Enseignement en Neurosciences (Román
et al., 1993).
Same procedures were performed at the next four follow-up
phases (at 2, 4, 8, and 10 years after baseline) allowing to consider
incident dementia screening over a total of 10 years of follow-up.
Anxiety Exposures Assessed in 1999/2001
Anxiety was assessed using the Spielberger State-Trait Anxiety
Inventory (STAI) (Spielberger, 1983)—a psychological inventory
based on a self-report basis. The STAI consists of 40 items based
on a 4-point Likert Scale and is commonly used to measure two
types of anxiety -the state anxiety (S-anxiety) and the trait anxiety
(T-anxiety). The T-anxiety subscale remains relatively stable over
time corresponding to anxiety level as a personal characteristic
and was considered alone in the present study. The total score of
the T-anxiety subscale ranges from 20 to 80, with higher scores
positively correlated with higher levels of anxiety symptoms.
An inventory of all drugs (prescription and over-the-
counter drugs) used during the preceding month of the clinical
examination was included in a standardized interview. Medical
prescriptions and, where feasible, the medications themselves
were checked by the interviewer. Use of anxiolytic drugs
including benzodiazepine, diphenylmethane, dibenzo-bicyclo-
octadiene, azaspirodecanedione derivatives, and carbamates,
mephenoxalone, gedocarnil, and etifoxin (ATC codes: N05B)
have then been considered.
Covariates Assessed in 1999/2001
Socio-Demographic
Socio-demographic variables consisted of sex, age, study center,
marital status (living alone/not living alone), educational level
(≤9 years/>9 years).
Health Behaviors
Health behaviors variables were smoking habits (never/ex or
current smoker) and alcohol consumption (null/moderate if< 15
glasses of alcohol per week for women and 22 for men, or
important if ≥ 15 for women and 22 for men, according to the
recommendations about low and high risk alcohol consumption
of the French Health High Authority (Haute Autorité de Santé,
2014).
Health Status
Health status related covariates included vascular risk factors:
body mass index (BMI) calculated from height and weight
measurements performed during the clinical examination at
baseline, dyslipidemia (plasma cholesterol≥6.20mmol/l or using
lipid-lowering drugs), diabetes (glycemia ≥ 5.55 mmol/l or
taking anti-diabetic treatment), hypertension (systolic/diastolic
blood pressure ≥140/≥90mm Hg or taking antihypertensive
drugs) and history of vascular pathology was composed of
self-reported variables and included history of stroke, angina
pectoris, myocardial infarction, coronary surgery, coronary
angioplasty, and arterial surgery of the legs for arteritis.
Limitations in activities of daily living (IADL) using the
Lawton–Brody scale (Lawton and Brody, 1969) (score >
0), and “low” cognitive performances defined by a score
≤ 27 on the MMSE have also been considered. Depressive
symptoms were assessed using the Center for Epidemiologic
Studies-Depression Scale (CESD) (Radloff, 1977). Participants
with CESD score >16 or taking antidepressant treatment
(ATC code: N06A) were considered as having depressive
symptoms.
Statistical Analyses
According to the norms established in the elderly population
(Bergua et al., 2012), T-anxiety subscale score was considered as
high trait anxiety for scores higher than the first quartile (score
≥ 44 defined as “high trait anxiety” being compared with the
score < 44, “low trait anxiety”).
Wilcoxon tests for quantitative variables and Chi2 tests for
qualitative variables were used to compare characteristics of
participants according to the dementia status at the end of the
follow-up period.
To examine the relationship between anxiety exposures and
risk of incident dementia over the 10-year follow-up period,
Cox proportional hazard regression models with delayed
entry (Lamarca et al., 1998) were performed with age as the
basic timescale and birth date as the time origin. Results
of proportional-hazard regression analyses were expressed
as hazard ratios (HR) with 95% confidence intervals (CI).
Participants who died or were lost to follow-up without
dementia were censored at their age of death or at the last
cognitive examination, respectively. The date of dementia onset
was set half way between the date of the last follow-up visit when
the subject was classified as normal and the date of diagnosis.
We first investigated the association between anxiety exposures
and risk of dementia in a model adjusted for age, sex, and
center. Then we progressively entered in 2 different multivariate
models the others possible confounders (education achievement,
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living alone, smoking habits, alcohol intake, BMI, vascular
risk factors, limitations in IADL, and cognitive performances).
Finally, to assess whether anxiety and depressive symptoms
were independently associated with the risk of dementia, a
fourth model was performed in which depressive symptoms and
anxiety were simultaneously included. In addition, contribution
of depression to the anxiety/risk of dementia relationship, as well
as the contribution of anxiety to the depressive symptoms/risk of
dementia association were examined in determining the percent
attenuations (MacKinnon and Dwyer, 1993). These percent
attenuations were calculated using the formula [(βANXIETY
− βANXIETY adjusted for DEP_SYMPTOMS)/βANXIETY] × 100 and
[(βDEP_SYMPTOMS − βDEP_SYMPTOMS adjusted for ANXIETY)/
βDEP_SYMPTOMS] × 100, where the βs are the coefficients
estimated from the Cox models.
The level of statistical significance was set at p< 0.05. Analyses
were conducted using SAS software, version 9.4 (SAS Institute).
RESULTS
Among the 5,234 participants with anxiety assessment at
baseline, a total of 378 new cases of dementia were diagnosed over
the 10 years of follow-up (57 diagnosed at the 2-year follow-up,
67 at the 4-year, 153 at the 8-year, and 101 at the 10-year follow-
up period) including 259 cases of probable AD (69%), 23 cases of
vascular dementia (6%), 50 cases of mixed dementia (13%), and
46 cases of other dementia types.
Seven hundred and fifty-two participants died (14%) and 1173
(22%) were lost to follow-up or refused to continue the study.
Participants who were lost to follow-up were significantly older,
had more frequently depressive symptomatology and anxiolytic
treatment, had lower MMSE scores at baseline but did not show
differences in T-anxiety subscale scores (data not shown).
Table 1 describes the characteristics of the 5,234 participants
included as a function of new-onset of dementia. Compared
to non-demented participants, those who developed dementia
over the 10 years of follow-up were significantly older, less likely
to reach a high educational achievement and more likely to
live alone, to have diabetes past history of vascular diseases,
depressive symptoms, IADL limitations, and lower cognitive
performances. They also were more likely to have higher anxiety
levels measured by the T-anxiety subscale and to use anxiolytic
drugs.
The comparison of characteristics of participants according
to tertiles of T-anxiety subscale score showed that participants
with high anxiety trait were more likely to have lower education
achievement, to live alone, to be non-smokers, to have low
alcohol consumption and to present dyslipidemia, lower BMI,
IADL limitations, depressive symptoms, and to take anxiolytic
drugs than participants with low anxiety trait (Table S1).
The associations between anxiety exposure and 10-year
incidence of dementia have been estimated by proportional
hazards models in which both anxiety trait and use of anxiolytic
drugs were included. Results are presented in Figure 2. After
adjustment for age, sex, and study center, anxiety levels and
use of anxiolytic drugs were both independently associated
with higher risk of developing dementia. Participants with
high trait anxiety showed a 28% increased risk of dementia
compared to those with low trait anxiety, those under anxiolytic
drugs had a 52% increased hazard ratio of dementia compared
to participants not using anxiolytics. Further adjustment for
education, marital status, health behaviors (smoking habits and
alcohol intake), BMI, history of vascular pathology, metabolic
disorder (hypertension, diabetes, dyslipidemia), incapacity and
cognitive impairment (Model 2 and Model 3) had little effect
on estimates (for T-anxiety scale: HRHigh vs. Low = 1.26; 95% CI:
1.01–1.57; for use of anxiolytic drugs: HRYes vs. No = 1.39, 95%
CI: 1.08–1.80).
Joint Association Between Anxiety
Exposures, Depressive Symptoms, and the
Risk of Incident Dementia
To further examine whether anxiety exposures and depressive
symptoms were independently associated with the risk
of incident dementia, a full adjusted model including
simultaneously anxiety exposures and depressive symptoms
was run. The T-anxiety subscale–dementia association after
adjustment for depressive symptoms was substantially attenuated
and did not significantly persist statistically. Similar observations
were reported for the anxiolytic drugs–dementia association
(Figure 2). Calculation of the percent attenuation showed that
depressive symptoms attenuated the association between high
trait anxiety and risk of dementia by 84.7% and the anxiolytic
drugs- dementia association by 22.4% (Table 2). Conversely,
high trait anxiety and use of anxiolytic drugs attenuated the
association between depressive symptoms and risk of dementia
by only 4.5 and 8.3%, respectively, and by 11% when included
simultaneously. After adjustment for both anxiety exposures,
only depressive symptoms remained significantly associated with
an increased risk of dementia [β = 0.409 (0.130), p < 0.001].
To further explore whether the association between anxiety
exposures and dementia risk depends on the depressive
symptoms, we performed supplementary analyses to assess the
interaction between trait anxiety and depressive symptoms. Main
analyses assessing the association between anxiety exposures
and dementia risk were also repeated by stratifying them
on depressive symptoms (Figure S1). Finally the risk of
dementia has been compared between the following four
groups of participants: no anxiety/no depressive symptoms
(reference group), no anxiety/depressive symptoms, anxiety/no
depressive symptoms, and anxiety/depressive symptoms, with
anxiety defined as having high trait anxiety or taking anxiolytic
treatment. Results reported in Figure S2 did not evidence
interaction between depressive symptoms and anxiety exposures
regarding dementia risk (p= 0.90 and p= 0.86, respectively).
DISCUSSION
The present study carried out in a large sample of elderly men
and women showed that anxiolytic drugs and having high trait
anxiety increased (by 40 and 25%, respectively) the risk of
dementia assessed over 10 years of follow-up. Those associations
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TABLE 1 | Baseline characteristics of the 5,234 participants as a function of new onset of dementia.
All participants New onset of dementia cases over the 10-y of follow-up
n = 5,234 Non cases n = 4,856 Dementia cases n = 378 p-value
†
n (%) or mean ± SD n (%) or mean ± SD n (%) or mean ± SD
SOCIOECONOMIC FACTORS
Sex, women 3,069 (58.5) 2,834 (58.5) 235 (62) 0.148
Age (years) 73.4 ± 5.2 73.2 ± 5.1 76.8 ± 5.6 <0.001
Study center
Bordeaux 813 (15.5) 749 (15.5) 64 (17) 0.053
Dijon 2,889 (55) 2,665 (55) 224 (59)
Montpellier 1,532 (29.5) 1,442 (29.5) 90 (24)
High education achievement* 2,139 (41) 2,010 (41) 129 (34) 0.006
Living alone 1,711 (33) 1,564 (32) 147 (39) 0.008
HEALTH BEHAVIOR
Smoking habits
Never/ex 4,938 (94) 4,576 (94) 362 (96)
current 296 (6) 280 (6) 16 (4) 0.260
Alcohol intake
Nul/moderate 4,301 (82) 3,982 (82) 319(84)
High* 933 (18) 874 (18) 59 (16) 0.500
HEALTH STATUS
Body mass index(kg/m2 ) 25.6 ± 4.0 25.6 ± 4.0 25.6 ± 4.2 0.430
Dyslipidemia* 2,977(57) 2,761 (57) 216 (57) 0.914
Hypertension* 3,953 (76) 3,659 (75) 294 (78) 0.290
Diabetes* 1,028 (20) 932 (19) 96 (25) 0.004
History of vascular pathology* 424 (8) 378 (8) 46 (12) 0.003
Cognitive impairment* 2,045 (39) 1,824 (38) 221 (58) <0.001
Incapacity* 341 (6.5) 276 (5.5) 65 (17) <0.001
Depressive symptomatology* 1,152 (22) 1,025 (21) 127 (34) <0.001
High anxiety trait * 1,672 (32) 1530 (32) 142 (38) 0.015
Use of anxiolytic drugs 738 (14) 655 (13) 83 (22) <0.001
*High education achievement has been defined by educational level >9 years, high alcohol intake by intake ≥15 glasses of alcohol/week for women (≥22 for men), dyslipidemia by
plasma cholesterol ≥6.20 mmol/L or use of lipids lowering drugs, hypertension by systolic/diastolic blood pressure ≥140mm Hg/≥90mm Hg or use of antihypertensive drugs, diabetes
by glycemia ≥5.55 mmol/l or antidiabetic treatment, history of vascular pathology (history of stroke, angina pectoris, myocardial infarction, coronary surgery, coronary angioplasty, and
arterial surgery of the legs for arteritis),cognitive impairment by MMSE score <27, incapacity by score>0 on the Lawton-Brody Scale, depressive symptomatology by CESD score ≥
16 or antidepressant treatment, high anxiety trait by STAI score ≥ 44.
†
Wilcoxon test for quantitative variables, and Chi2 test for qualitative variables.
were independent of a large panel of socio-demographic, health
behaviors, cardio-metabolic disorders, and additional age-related
disorders such as cardiovascular diseases, activity limitations,
and cognitive deficit. However those anxiety exposures-dementia
associations were shaped by depressive symptoms playing a
strong role of confounder.
Those results are in agreement with those of the literature.
In the Caerphilly dementia study (Gallacher et al., 2009), no
significant association between high trait anxiety and risk of
developing dementia were observed in 1,481 men followed for a
17-year period when adjusted for depression (evaluated with the
30-item general health questionnaire). However, as long as we
did not consider depressive symptoms in our statistical models,
our findings -showing a significant increased risk of dementia
in participants with anxiety- are in line with the prospective
studies in which confounding role of depressive symptoms was
not considered and carried out in general populations (Wilson
et al., 2011; Kassem et al., 2017) as well as inMCI patients (Palmer
et al., 2007; Rosenberg et al., 2013).
In our sample, we observed that participants with a high
score to T-anxiety subscale of the STAI (≥44) had a 25%
higher risk of developing dementia than participants with a
score <44 independently of socio-economic, health behavior,
or health status factors. However, introduction of depressive
symptomatology as an adjustment factor strongly attenuated
(84.7%) the relationship between trait anxiety and risk of
dementia, which was no longer significant. Conversely, anxiety
trait and use of anxiolytic drugs did not fundamentally change
the relationship between depressive symptoms and risk of
dementia, which remained significant. In addition, the absence of
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FIGURE 2 | Relationship between anxiety trait, use of anxiolytic drugs and 10-year risk of incident dementia (Multivariate Cox Proportional Hazard Models, n = 5,234,
n. event = 378).
Model 1: Adjustment for age, sex, center.
Model 2: Model 1 and smoking habits, alcohol intake, education, living alone.
Model 3: Model 2 and body mass index, history of vascular pathology, hypertension, diabetes, dyslipidemia, incapacity, MMSE at baseline.
Model 4: Model 3 and depressive symptoms.
interaction between depressive symptoms and anxiety exposures
regarding dementia risk did not support the hypothesis that
the direction and the magnitude of the anxiety exposure–
dementia risk association depends on the depressive symptoms.
Our findings thus suggest that depressive symptomatology is
a strong confounder of the anxiety-dementia relationship. In
other words, when depressive symptomatology is not taken
into account, the association between trait anxiety and risk
of dementia may actually reflect the comorbidity of anxiety
with depression. Co-occurrence of depression and anxiety
are common throughout the life cycle (Regier et al., 1988;
Beekman et al., 1998; Kessler et al., 2010). However, the
mechanisms underlying this close relationship are still under
debate. It remains unclear whether anxiety and depression share
a common etiology (Roy et al., 1995; Grant et al., 2009), or
whether anxiety is a prodromal stage of depression (Potvin
et al., 2013). Consideration of a dimensional classification
including both depression and anxiety has been suggested
to be more appropriate in the elderly (Schoevers et al.,
2003), and some prospective studies have even shown that
the related concept of psychological distress, a mixture of
anxiety and depression, was associated with AD (Wilson
et al., 2003, 2005). Similarly, an overlap between anxiolytic
treatment and depression is frequent. Indeed, anxiolytic drugs
are commonly prescribed to people with depression in order
to improve their symptoms more quickly, mitigate concomitant
anxiety, and improve antidepressant treatment continuation
(Bushnell et al., 2017). In our study, we observed that
while the relationship between anxiety exposures and risk of
dementia was substantially attenuated by depressive symptoms,
anxiety exposures did not change the statistical association
between depressive symptomatology and risk of dementia which
remained significant. Our findings do not allow to conclude on
the nature of the relationship between anxiety exposures and
depression, but suggest that, whatever the nature of the link
between those two entities, it is the underlying depression that
drives the association between anxiety exposures and dementia.
In addition, concomitant anxiety and depression do not increase
the dementia risk estimated in the presence of depression
alone. Taken together, those findings designate depression as
the neuropsychiatric symptom to focus on in the prevention of
dementia risk.
The design of the present study constitutes its main strength.
Indeed, the large cohort, as well as the length of the follow-
up period, provide sufficient power to estimate precisely the
magnitude of the effect of anxiety trait and depression on
dementia (all causes confounded) risk. The validated dementia
diagnosis by an independent committee limits classification bias,
while the large number of documented potential confounders,
as well as the adjustment for use of anxiolytic drugs, reduce
those of confounding. Limitations of our study should also be
considered. Participants who were excluded from the analysis
were more likely to have higher T-anxiety score at baseline and
might have been at higher risk of dementia. This selection bias has
probably led to an underestimation of the association reported
between T-anxiety score and risk of dementia. Additionally,
anxiety trait has been self-reported using the T-anxiety subscale
of the Spielberger STAI. Even if its use in epidemiological
framework has been validated (Spielberger, 1983), it does
not capture the anxiety disorders and might reflect some
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TABLE 2 | Joint association between anxiety exposures, depression and 10-year risk of incident dementia.
Each component alone β adjusted (SE)* p
ANXIETY EXPOSURES
Anxiety trait (high vs. low) 0.229 (0.112) 0.040
Use of anxiolytic drugs (yes vs. no) 0.331 (0.131) 0.011
DEPRESSIVE SYMPTOMATOLOGY (YES VS. NO) 0.555 (0.114) <0.001
Joint association β adjusted (SE)
†
p % attenuation¶
Anxiety trait (high vs. low) with additional adjustment for depressive symptomatology 0.035 (0.124) 0.781 84.7%
Anxiolytic treatment (yes vs. no) with additional adjustment for depressive symptomatology 0.257 (0.132) 0.052 22.4%
Depressive symptomatology (yes vs. no) with additional adjustment for anxiety trait 0.530 (0.128) <0.001 4.5%
Depressive symptomatology (yes vs. no) with additional adjustment for use of anxiolytic drugs 0.509 (0.117) <0.001 8.3%
Depressive symptomatology (yes vs. no) with additional adjustment for anxiety trait and use of anxiolytic drugs 0.494 (0.130) <0.001 11.0%
*Adjustment for age, sex, center, smoking habits, alcohol intake, education, living alone, body mass index, history of vascular pathology, hypertension, diabetes, dyslipidemia, incapacity,
MMSE at baseline.
†
Additional adjustment for depressive symptomatology or anxiety exposures.
¶The percentages by which the associations were attenuated were determined using the formula [(βANXIETY − βANXIETYadjustedforDEPRESSION )/βANXIETY ] × 100 and [(βDEPRESSION
− βDEPRESSIONadjustedforANXIETY )/βDEPRESSION ] ×100, where the βs are the coefficients estimated from the cox models. For instance, the percent attenuation of depression
in the relationship between high STAI score and risk of incident dementia was determined using the formula [(βSTAI − βSTAIadjustedforDEPRESSION )/βSTAI ] ×100, βSTAI = 84.7.
The percent attenuation of anxiolytic treatment in the relationship between depression and risk of incident dementia was determined using the formula [(βDEPRESSION −
βDEPRESSIONadjustedforANXIOLYTICTREATMENT )/βDEPRESSION ] × 100, βDEPRESSION = 8.3.
aspects of depressive symptomatology. Thus, our findings on
associations between anxiety trait and dementia risk in regard
to depressive symptoms cannot be extrapolated to anxiety
disorders.
Finally, we were not able to further conduct analyses
by considering dementia subtypes (AD, vascular, and mixed
dementias). Additional studies assessing the anxiety exposures,
depression in relation to different dementia subtypes may
provide a better understanding of anxiety, depressive symptoms
and dementia relationships.
CONCLUSION
In this study carried out in a large cohort of older community
dwellers, we showed how associations between anxiety trait and
dementia are shaped by depressive symptoms and possibly reflect
the high level of comorbidity between anxiety trait and depressive
symptoms. Further research is needed to replicate our findings
and extrapolate our results to anxiety disorders.
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